Immunization schedule in India

Dr. Ajay Jain Dr. Ajay Jain Nov 2, 2017 1936 0

Immunization schedule in India

IAP Immunization Schedule 2016 (Tabular form)

IAP recommended vaccines for routine use

Age
(completed weeks/months/years)		 Vaccines Comments
Birth BCG
OPV 0
Hep-B 1		 Administer these vaccines to all newborns before hospital discharge
6 weeks DTwP 1
IPV 1
Hep-B 2
Hib 1
Rotavirus 1
PCV 1

DTP:

  • DTaP vaccine/combinations should preferably be avoided for the primary series
  • DTaP vaccine/combinations should be preferred in certain specific circumstances/conditions only
  • No need of repeating/giving additional doses of whole-cell pertussis (wP) vaccine to a child who has earlier completed their primary schedule with acellular pertussis (aP) vaccine-containing products

Polio:

  • All doses of IPV may be replaced with OPV if administration of the former is unfeasible
  • Additional doses of OPV on all supplementary immunization activities (SIAs)
  • Two doses of IPV instead of 3 for primary series if started at 8 weeks, and 8 weeks interval between the doses
  • No child should leave the facility without polio immunization (IPV or OPV), if indicated by the schedule
  • See footnotes under figure titled IAP recommended immunization schedule (with range) for recommendations on intradermal IPV

Rotavirus:

  • 2 doses of RV1 and 3 doses of RV5 & RV 116E
  • RV1 should be employed in 10 & 14 week schedule, 10 & 14 week schedule of RV1 is found to be more immunogenic than 6 & 10 week schedule
10 weeks DTwP 2
IPV 2
Hib 2
Rotavirus 2
PCV 2

Rotavirus:

  • If RV1 is chosen, the first dose should be given at 10 weeks
14 weeks DTwP 3
IPV 3
Hib 3
Rotavirus 3
PCV 3

Rotavirus:

  • Only 2 doses of RV1 are recommended.
  • If RV1 is chosen, the 2nd dose should be given at 14 weeks
6 months OPV 1
Hep-B 3

Hepatitis-B:

  • The final (3rd or 4th) dose in theHepB vaccine series should be administered no earlier than age 24 weeks and at least 16 weeks after the first dose.
9 Months OPV 2
MMR-1

Hepatitis-B:

  • Measles-containing vaccine ideally should not be administered before completing 270 days or 9 months of life;
  • The 2nd dose must follow in 2nd year of life;
  • No need to give stand-alone measles vaccine
9-12 months Typhoid Conjugate Vaccine
  • Currently, two typhoid conjugate vaccines, Typbar-TCV® and PedaTyph® available in Indian market;either can be used
  • An interval of at least 4 weeks with the MMR vaccine should be maintained while administering this vaccine
12 months Hep-A 1

Hepatitis-A:

  • Single dose for live attenuated H2-strain Hep-A vaccine
  • Two doses for all inactivated Hep-A vaccines are recommended
15 months MMR 2
Varicella 1
PCV booster

MMR:

  • The 2nd dose must follow in 2nd year of life
  • However, it can be given at anytime 4-8 weeks after the 1st dose

 

 

Varicella: The risk of breakthrough varicella is lower if given 15 months onwards
16 to 18 Months DTwP B1/DTaP B1
IPV B1
Hib B1		 The first booster (4th dose) may be administered as early as age 12 months, provided at least 6 months have elapsed since the third dose

 

DTP:

  • First & second boosters should preferably be of DTwP
  • Considering a higher reactogenicity of DTwP, DTaP can be considered for the boosters
18 months Hep-A 2

Hepatitis A:

2nd dose for inactivated vaccines only
2 years Booster of Typhoid
Conjugate Vaccine
  • A booster dose of Typhoid conjugate vaccine (TCV), if primary dose is given at 9-12 months
  • A dose of Typhoid Vi-polysaccharide(Vi-PS) vaccine can be given if conjugate vaccine is not available or feasible;
  • Revaccination every 3 years with Vi-polysaccharide vaccine
  • Typhoid conjugate vaccine should be preferred over Vi-PS vaccine
4 to 6 years DTwP B2/DTaP B2
OPV 3
Varicella 2
MMR 3

Varicella:

the 2nd dose can be given at anytime 3 months after the 1st dose.

MMR:

the 3rd dose is recommended at 4-6 years of age.
10 to 12 years Tdap/Td
HPV

Tdap:

is preferred to Td followed by Td every 10 years

HPV:

  • Only 2 doses of either of the two HPV vaccines for adolescent/preadolescent girls aged 9-14 years;
  • For girls 15 years and older, and immunocompromised individuals 3 doses are recommended
  • For two-dose schedule, the minimum interval between doses should be 6 months.
  • For 3 dose schedule, the doses can be administered at 0, 1-2 (depending on brand) and 6 months